US-based healthcare investor MPM Capital has promoted principals Ashley Dombkowski, Steven St. Peter and Ilan Zipkin to general partners.
Dombkowski and Zipkin are based in MPM’s San Francisco office, while St. Peter is based in Boston.
Dombkowski joined MPM in 2000 from hedge fund Tiger Management, where she was a healthcare equity analyst covering biotech, medical device, and pharmaceutical companies. St. Peter began working for MPM in 2003, with nearly five years experience in private equity, having worked previously at Apax Partners and The Carlyle Group. Zipkin joined MPM in 2000 from BioCentury Publications where he had spent four years covering both public and private companies in the biotechnology sector, most recently as science editor.
The promotions follow the hiring of healthcare investor Vaughn Kailian as general partner back in May. Kailian had previously worked on several of MPM’s portfolio companies, including ViaCell and Elixir.
MPM invests globally in early-stage startups as well as large-cap public companies, in the biopharma and medical device sectors. The firm manages more than $2.1 billion in assets through the MPM BioVentures group of venture capital funds and the MPM BioEquities public market funds. At the end of May, MPM completed its first UK investment with the close of a £31.6 million (€46 million; $58 million) series B financing of Abingdon, Oxfordshire-headquartered drug discovery company Oxagen.
The financing round, reportedly the largest biopharmaceutical investment in the UK and Europe so far this year, was joined by existing investors: 3i, Abingworth, Advent Ventures, SV Life Sciences and The Wellcome Trust.